Industry Insights · Artificial Heart & Circulatory Support
Capital bets on the artificial heart: the 'crown jewel' and the first-IPO race
As the 'crown jewel' of medical devices, the artificial heart has drawn intense capital interest.
Why the 'crown jewel'
The artificial heart has extreme technical barriers, large clinical value and a sizeable market — the crown jewel of high-value implants, and a natural target for industrial and cross-over capital.
Strategic stakes and a valuation jump
A listed strategic shareholder took a ~RMB 102M stake in a leading artificial-heart firm in 2019 and kept investing; the firm completed a pre-IPO round with valuation up about sixfold in three years — a clear sign of capital's conviction.
A key step to going global
Its new-generation BrioVAD won US FDA clinical-trial clearance in 2024, becoming China's first and only active implantable device cleared for a US trial — a landmark for Chinese high-end active implants going global.
The BIO angle
FAQ
Why is the artificial heart the 'crown jewel'?
High technical barriers, large clinical value and a sizeable market make it one of the most emblematic high-value implant directions.
What does FDA clinical clearance of an active implant mean?
It allows a US clinical trial — a key step into mainstream Western regulation and clinical evaluation, but not marketing approval.
Is this investment advice?
No. It is an industry and capital overview, with no investment recommendation.
Related reading
- Carmat Aeson Total Artificial Heart: Design and Materials of the EU's Only Commercial TAH | BIO Insights
- Percutaneous RVAD Enters the Fast Track: the Overlooked Right Heart and a Materials Barrier | BIO Insights
- China's Maglev Artificial Heart: from First Implant to the Global High-End Market | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.